Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Dec 31, 2023
Revenue for the quarter increased compared to both the immediately preceding quarter and the same period last year. The growth reflects a continuation of the upward trend seen throughout the year.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 Q4
Revenue for the quarter increased compared to both the immediately preceding quarter and the same period last year. The growth reflects a continuation of the upward trend seen throughout the year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.5B
Revenue reported for this quarter.
Quarter-over-quarter
+1.4%
Change from the immediately preceding quarter.
Year-over-year
+9.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$9.9B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $2.4B | +13.2% |
| Jun 30, 2023 | $2.5B | +13.5% |
| Sep 30, 2023 | $2.5B | +6.4% |
| Dec 31, 2023 | $2.5B | +9.3% |
Revenue performance
The reported revenue rose, marking a modest sequential gain.
Quarterly comparison
Compared to the prior quarter, revenue was slightly higher, and compared to the same quarter one year earlier, revenue showed a stronger increase.
What to watch
The slight sequential increase follows a period of relatively stable revenue levels in recent quarters.